BioSpace News Archive

Vital Metrix, a late-stage medical device software company developing a non-invasive cardiac output measurement solution, announced today that it had been selected to present at the TCT 2019 Scientific Symposium in San Francisco at the end of September.

Galderma, a global leader in skin health focused on developing innovative aesthetic solutions, recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114

Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that Professor Maurizio Scarpa, MD, PhD, Director of the Regional Coordinating Center for Rare Disease, Udine University Hospital, Udine, Italy and Professor of Pediatrics, University of Padova, Italy, will serve as EU Coordinating Investigator for the company’s upcoming Phase III pivotal trial

Multidrug-resistant bacteria limit the effectiveness of antibiotics, and to stop these “superbacteria,” we need to understand how their resistance works.

Dial-in Numbers U.S. / Canada Dial-in Number: (866) 502-9859 International Dial-in Number: (574) 990-1362 Conference ID: 2973359

NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a gold sponsor at the EUROSPINE 2019 Annual Meeting held October 16-18, 2019 in Helsinki, Finland.

First patient enrolled in the investigator initiated CATRIPCA study at the Léon Bérard Cancer Center in Lyon, France

BioConsortia, Inc., innovator of microbial solutions for plant trait enhancement and yield improvement, has added a wheat seed treatment to the growing list of new biological products moving to registration phase.

Newk’s Cares philanthropy marks sixth year

Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. (CTFH), taking on previously undruggable targets.